{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:44:29Z","timestamp":1776473069549,"version":"3.51.2"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s13311-023-01404-1","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T10:02:38Z","timestamp":1689156158000},"page":"1305-1315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans"],"prefix":"10.1016","volume":"20","author":[{"given":"Diane","family":"Merino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre O.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise K.","family":"Van Obberghen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Destere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Lanteri-Minet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-530X","authenticated-orcid":false,"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"International Headache Society","year":"2018","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1007\/s13311-023-01404-1_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system-40 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database","volume":"23","author":"G\u00e9rard","year":"2022","journal-title":"J Headache Pain"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ram\u00edrez","year":"2020","journal-title":"Pain"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1007\/s13311-023-01404-1_bib7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","article-title":"Mechanisms of action of the 5-HT1B\/1D receptor agonists","volume":"59","author":"Tepper","year":"2002","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1007\/s13311-023-01404-1_bib8","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","article-title":"Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review","volume":"37","author":"Leroux","year":"2020","journal-title":"Adv Ther"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","article-title":"Consensus statement: Cardiovascular safety profile of triptans (5-HT1B\/1D agonists) in the acute treatment of migraine","volume":"44","author":"Dodick","year":"2004","journal-title":"Headache"},{"issue":"9","key":"10.1007\/s13311-023-01404-1_bib10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40263-022-00948-8","article-title":"New oral drugs for migraine","volume":"36","author":"Karsan","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","article-title":"Lasmiditan mechanism of action \u2013 review of a selective 5-HT1F agonist","volume":"21","author":"Clemow","year":"2020","journal-title":"J Headache Pain"},{"issue":"24","key":"10.1007\/s13311-023-01404-1_bib12","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1111\/bph.14832","article-title":"Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan","volume":"176","author":"Rubio-Beltr\u00e1n","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1007\/s13311-023-01404-1_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0333102419855080","article-title":"Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN","volume":"39","author":"Krege","year":"2019","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2732","article-title":"Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls","volume":"35","author":"Pearlman","year":"2020","journal-title":"Hum Psychopharmacol"},{"key":"10.1007\/s13311-023-01404-1_bib15","author":"American Headache Society"},{"key":"10.1007\/s13311-023-01404-1_bib16","author":"FDA"},{"key":"10.1007\/s13311-023-01404-1_bib17","series-title":"Meeting highlights from the Committee for Medicinal Products Human Use (CHMP) 20\u201323 June 2022 [Internet]","author":"EMA","year":"2022"},{"key":"10.1007\/s13311-023-01404-1_bib18","author":"EMA"},{"key":"10.1007\/s13311-023-01404-1_bib19","author":"Uppsala Monitoring Centre"},{"key":"10.1007\/s13311-023-01404-1_bib20","author":"Centre UM"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib21","first-page":"409","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther Innov Regul Sci"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4212\/cjhp.v71i5.2842","article-title":"Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting","volume":"71","author":"Gautron","year":"2018","journal-title":"Can J Hosp Pharm"},{"key":"10.1007\/s13311-023-01404-1_bib23","author":"FDA"},{"key":"10.1007\/s13311-023-01404-1_bib24","author":"MedDRA"},{"issue":"6","key":"10.1007\/s13311-023-01404-1_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting: QUANTITATIVE SIGNAL DETECTION","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidem Drug Safe"},{"issue":"4","key":"10.1007\/s13311-023-01404-1_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1007\/s13311-023-01404-1_bib28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","article-title":"Migraine and its psychiatric comorbidities","volume":"87","author":"Minen","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1007\/s13311-023-01404-1_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1468-2982.2004.00839.x","article-title":"Psychiatric comorbidity in migraine: a review","volume":"25","author":"Radat","year":"2005","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1007\/s13311-023-01404-1_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10194-010-0282-4","article-title":"Migraine and psychiatric comorbidity: a review of clinical findings","volume":"12","author":"Antonaci","year":"2011","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0165-1781(91)90102-U","article-title":"Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults","volume":"37","author":"Breslau","year":"1991","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1007\/s13311-023-01404-1_bib32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1212\/WNL.54.2.308","article-title":"Headache and major depression: is the association specific to migraine?","volume":"54","author":"Breslau","year":"2000","journal-title":"Neurology"},{"issue":"S1","key":"10.1007\/s13311-023-01404-1_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10072-009-0071-5","article-title":"Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications","volume":"30","author":"Baskin","year":"2009","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-023-01404-1_bib34","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.pain.2013.07.021","article-title":"Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain","volume":"154","author":"Noseda","year":"2013","journal-title":"PAIN\u00ae"},{"issue":"7","key":"10.1007\/s13311-023-01404-1_bib35","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/head.13101","article-title":"Aura and other neurologic dysfunction in or with migraine","volume":"57","author":"Kissoon","year":"2017","journal-title":"Headache"},{"issue":"3","key":"10.1007\/s13311-023-01404-1_bib36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1468-2982.2007.01278.x","article-title":"Treatment-emergent CNS symptoms following triptan therapy are part of the attack","volume":"27","author":"Goadsby","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-023-01404-1_bib37","author":"BDPM"},{"issue":"7","key":"10.1007\/s13311-023-01404-1_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1124\/dmd.31.7.861","article-title":"Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein","volume":"31","author":"Evans","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1007\/s13311-023-01404-1_bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","article-title":"Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2012","journal-title":"Lancet Neurol"},{"issue":"24","key":"10.1007\/s13311-023-01404-1_bib41","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1007\/s13311-023-01404-1_bib42","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1007\/s13311-023-01404-1_bib43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jcph.1543","article-title":"Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study","volume":"60","author":"Wilbraham","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1007\/s13311-023-01404-1_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112972","article-title":"Antipsychotic abuse, dependence, and withdrawal in the pediatric population: a real-world disproportionality analysis","volume":"10","author":"Merino","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","article-title":"Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis","volume":"21","author":"Hou","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1756285614562419","article-title":"The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine","volume":"8","author":"Reuter","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1007\/s13311-023-01404-1_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00210-005-1036-8","article-title":"[3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain","volume":"371","author":"Lucaites","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"10.1007\/s13311-023-01404-1_bib48","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1007\/s13311-023-01404-1_bib49","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0006-3223(91)90326-H","article-title":"PET in generalized anxiety disorder","volume":"29","author":"Wu","year":"1991","journal-title":"Biol Psychiat"},{"issue":"7","key":"10.1007\/s13311-023-01404-1_bib50","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00415-015-7687-6","article-title":"On visual hallucinations and cortical networks: a trans-diagnostic review","volume":"262","author":"Carter","year":"2015","journal-title":"J Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01404-1_bib51","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/aian.AIAN_30_21","article-title":"Lasmiditan: a new promising drug in migraine","volume":"24","author":"Prakash","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"issue":"2","key":"10.1007\/s13311-023-01404-1_bib52","first-page":"259","article-title":"Autoscopy: the experience of oneself as a double","volume":"5","author":"Grotstein","year":"1983","journal-title":"Hillside J Clin Psychiatry"},{"key":"10.1007\/s13311-023-01404-1_bib53","author":"FDA"},{"issue":"2","key":"10.1007\/s13311-023-01404-1_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0333102414550416","article-title":"Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies","volume":"35","author":"Roberto","year":"2015","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1007\/s13311-023-01404-1_bib55","first-page":"342","article-title":"Consider cardiovascular risk factors before prescribing triptans for migraine","volume":"98","author":"Vu","year":"2018","journal-title":"Am Fam Physician"},{"key":"10.1007\/s13311-023-01404-1_bib56","author":"FDA"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1574884712666170419155048","article-title":"The journey of the non-vascular relief for migraine: from \u2018triptans to \u2018ditans'","volume":"12","author":"Xavier","year":"2017","journal-title":"Curr Clin Pharmacol"},{"issue":"8","key":"10.1007\/s13311-023-01404-1_bib58","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/head.13601","article-title":"Getting to the heart of the matter: migraine, triptans, DHE, ditans, CGRP antibodies, first\/second-generation gepants, and cardiovascular risk","volume":"59","author":"Mathew","year":"2019","journal-title":"Headache"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib59","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0090-9556(25)08158-9","article-title":"Disposition of sumatriptan in laboratory animals and humans","volume":"21","author":"Dixon","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"Shapiro","year":"2019","journal-title":"J Headache Pain"},{"issue":"5","key":"10.1007\/s13311-023-01404-1_bib61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"issue":"3","key":"10.1007\/s13311-023-01404-1_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-200124030-00006","article-title":"Temporal patterns of NSAID spontaneous adverse event reports","volume":"24","author":"Wallenstein","year":"2001","journal-title":"Drug-Safety"},{"issue":"6","key":"10.1007\/s13311-023-01404-1_bib63","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1007\/s13311-023-01404-1_bib64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0333102419889350","article-title":"Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans","volume":"40","author":"Knievel","year":"2020","journal-title":"Cephalalgia"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01404-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01404-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01404-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:13:13Z","timestamp":1761808393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1878747923019293"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01404-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01404-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}